ClinicalTrials.gg

Program

AOC 1001

A development code. Also written as “AOC 1001 (del-desiran)” and “Del-desiran (AOC 1001)”.

In Novartis's pipeline, siRNA DMPK knockdown. Its studies are mostly in Myotonic Dystrophy, led by Novartis.

Furthest: phase 3, since May 8, 20244 company-led studies, 1 open or runningNext primary completion: Oct 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis41 open or runningphase 3since May 8, 2024Aug 24, 2021Oct 2030phase 3 · NCT07008469
  • Named in Novartis’s own pipeline as EWF980 (del-desiran), phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2021First study: phase 2 study in Myotonic DystrophyFirst studyNCT05027269 · 39 enrolled · United States
  2. Jul 27, 2022Phase 2 study in Muscular DystrophiesNCT05479981 · 37 enrolled · United States
  3. May 8, 2024Phase 3 study in Myotonic DystrophyNCT06411288 · 159 enrolled · United States, Canada, Denmark and more
  4. May 29, 2025Phase 3 study in Myotonic DystrophyNCT07008469 · 199 planned · United States, Canada, Denmark and more

Ahead

  1. Oct 2030Primary completion: phase 3 study in Myotonic DystrophyNCT07008469

TargetBeta

“siRNA DMPK knockdown”the company's pipeline, read by Claude · source

Other programs on DMPK

ProgramCompanyFurthest phaseStudies
SAR446268Sanofiphase 21

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07008469Myotonic Dystrophy · United States, Canada, Denmark and more3By invitationOct 2030199
NCT06411288Myotonic Dystrophy · United States, Canada, Denmark and more3CompletedJul 23, 2026159
NCT05479981Muscular Dystrophies · United States2CompletedSep 5, 202537
NCT05027269Myotonic Dystrophy · United States2CompletedFeb 14, 202339

How it is read

Names in the registry

  • “AOC 1001”, 2 entries
  • “AOC 1001 (del-desiran)”, 1 entry
  • “Del-desiran (AOC 1001)”, 1 entry

Codes read as this program: AOC1001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.